Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Traumakine
Highest Development Status: Phase III Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 14, 2021
The agreement clarifies Faron's intellectual property position in the U.S. ahead of any launch of Traumakine for the treatment of capillary leak and systemic inflammatory response syndromes including acute respiratory distress syndrome (ARDS) in the U.S.